Celldex Therapeutics (CLDX) News Today $26.32 +0.12 (+0.46%) (As of 11:03 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period State Street Corp Sells 173,932 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)State Street Corp decreased its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 6.5% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,485,156 shares of the biopharmaceutical company's stock after selling 17December 17 at 3:34 AM | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Trading Down 5.5% - Should You Sell?Celldex Therapeutics (NASDAQ:CLDX) Trading Down 5.5% - Time to Sell?December 13, 2024 | marketbeat.comBNP Paribas Financial Markets Purchases 21,013 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)BNP Paribas Financial Markets raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 293.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 28,181 shares of the biopharmaceutical cDecember 11, 2024 | marketbeat.comXTX Topco Ltd Makes New $1.56 Million Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX)XTX Topco Ltd acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 45,917 shares of the biopharmaceutical company's stockDecember 9, 2024 | marketbeat.comWellington Management Group LLP Buys 1,167,659 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Wellington Management Group LLP boosted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 14.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,243,599 sharDecember 8, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Sells 24,010 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)The Manufacturers Life Insurance Company lessened its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 18.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 105,777 shares of the biopharmaceutical company'sDecember 8, 2024 | marketbeat.comReadystate Asset Management LP Makes New $6.10 Million Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Readystate Asset Management LP acquired a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 179,518 shares of the biopharmaceutical company's stock, valued at apDecember 5, 2024 | marketbeat.comRedmile Group LLC Has $22.34 Million Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Redmile Group LLC lessened its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 8.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 657,175 shares of the biopharmaceutical compDecember 5, 2024 | marketbeat.comCinctive Capital Management LP Reduces Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Cinctive Capital Management LP cut its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 62.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 33,797 shares of the biopharmaceutical company's stock after selling 57,330 shDecember 4, 2024 | marketbeat.comFmr LLC Has $204.77 Million Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Fmr LLC trimmed its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 23.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,024,416 shares of the biopharmaceutDecember 3, 2024 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has received an average rating of "Moderate Buy" from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, six have assigned a buDecember 3, 2024 | marketbeat.comBellevue Group AG Acquires 100,000 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Bellevue Group AG boosted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 3.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,071,615 shares of the biopharmaceutical companDecember 1, 2024 | marketbeat.comIntech Investment Management LLC Makes New $871,000 Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Intech Investment Management LLC purchased a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 25,632 shares of the biopharmaceutical company's stock, valued at approximatelyNovember 29, 2024 | marketbeat.comFisher Asset Management LLC Purchases 253,808 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Fisher Asset Management LLC raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 210.6% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 374,352 shares of the biopharmaceutical company's stock after acquiring aNovember 28, 2024 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by Algert Global LLCAlgert Global LLC cut its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 27.3% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 54,983 shares of the biopharmaceutical company's stock after selling 20,631 sharesNovember 28, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for CLDX FY2025 Earnings?Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Stock analysts at HC Wainwright boosted their FY2025 EPS estimates for shares of Celldex Therapeutics in a note issued to investors on Wednesday, November 20th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical compaNovember 22, 2024 | marketbeat.comJennison Associates LLC Has $45.02 Million Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Jennison Associates LLC lifted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 32.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,324,410 shares of the biopharmaceutical company's stock after purchasing an additionalNovember 22, 2024 | marketbeat.comCelldex’s Barzolvolimab: A Promising Therapy with Strong Safety and Efficacy Profile Boosts Buy RatingNovember 22, 2024 | markets.businessinsider.comCelldex announces first patient dosed in Phase 1a study of CDX-622November 21, 2024 | markets.businessinsider.comBeyond The Numbers: 11 Analysts Discuss Celldex Therapeutics StockNovember 20, 2024 | benzinga.comCelldex Therapeutics Reports Q3 2024 Progress and FinancialsNovember 20, 2024 | markets.businessinsider.comCelldex Therapeutics (NASDAQ:CLDX) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Wednesday.November 20, 2024 | marketbeat.comCelldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory DiseasesNovember 20, 2024 | globenewswire.comCelldex Therapeutics (NASDAQ:CLDX) Reaches New 52-Week Low - What's Next?Celldex Therapeutics (NASDAQ:CLDX) Sets New 1-Year Low - What's Next?November 15, 2024 | marketbeat.comSteven Cohen's Strategic Reduction in Celldex Therapeutics HoldingsNovember 15, 2024 | gurufocus.comAnthony S. Marucci Purchases 11,500 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) StockNovember 13, 2024 | insidertrades.comInsider Buying: Celldex Therapeutics Inc (CLDX) President & CEO Acquires SharesNovember 12, 2024 | gurufocus.comInsider Buying: Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Buys 11,500 Shares of StockCelldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) CEO Anthony S. Marucci purchased 11,500 shares of the business's stock in a transaction that occurred on Monday, November 11th. The stock was acquired at an average cost of $26.82 per share, with a total value of $308,430.00. Following the completion of the acquisition, the chief executive officer now directly owns 40,284 shares of the company's stock, valued at $1,080,416.88. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.November 12, 2024 | marketbeat.comCelldex Therapeutics to Present at Upcoming Investor ConferencesNovember 11, 2024 | globenewswire.comHC Wainwright Has Positive Forecast for CLDX FY2024 EarningsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - HC Wainwright raised their FY2024 EPS estimates for Celldex Therapeutics in a report released on Thursday, November 7th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings of ($2.39) per sNovember 11, 2024 | marketbeat.comResearch Analysts Set Expectations for CLDX FY2024 EarningsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Leerink Partnrs dropped their FY2024 EPS estimates for shares of Celldex Therapeutics in a report released on Wednesday, November 6th. Leerink Partnrs analyst T. Smith now expects that the biopharmaceutical company will post earnings of ($2November 11, 2024 | marketbeat.comFY2028 Earnings Estimate for CLDX Issued By Leerink PartnrsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2028 earnings per share estimates for shares of Celldex Therapeutics in a research note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst T. Smith now anticipateNovember 8, 2024 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from BrokeragesCelldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine analysts that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, six have given a buy recommendation and oneNovember 8, 2024 | marketbeat.comCantor Fitzgerald Reaffirms Their Buy Rating on Celldex (CLDX)November 7, 2024 | markets.businessinsider.comCelldex Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 6, 2024 | globenewswire.comCelldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month Low - Time to Sell?Celldex Therapeutics (NASDAQ:CLDX) Sets New 52-Week Low - Time to Sell?November 5, 2024 | marketbeat.comEmerald Advisers LLC Acquires 257,773 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Emerald Advisers LLC increased its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 129.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 456,202 shares of the biopharmNovember 3, 2024 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Shares Down 6% - Here's What HappenedCelldex Therapeutics (NASDAQ:CLDX) Stock Price Down 6% - Time to Sell?October 29, 2024 | marketbeat.comCelldex’s Promising Phase 2 Results and Strong Financial Position Warrant a Buy RatingOctober 28, 2024 | markets.businessinsider.comCelldex selloff creates buying opportunity, says GuggenheimOctober 28, 2024 | markets.businessinsider.comCelldex Therapeutics' (CLDX) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Monday.October 28, 2024 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) pulls back 6.1% this week, but still delivers shareholders fantastic 57% CAGR over 5 yearsOctober 28, 2024 | finance.yahoo.comCelldex Therapeutics' Barzolvolimab Meets Phase 2 Study Endpoints For Chronic Inducible UrticariaOctober 27, 2024 | markets.businessinsider.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Position Lifted by Novo Holdings A SNovo Holdings A S lifted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 13.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 963,663 shares of the bioOctober 27, 2024 | marketbeat.comCelldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible UrticariaOctober 26, 2024 | globenewswire.comCelldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024October 25, 2024 | globenewswire.comCelldex Therapeutics (CLDX): A Top Small-Cap Growth Stock with Promising Clinical ResultsOctober 24, 2024 | msn.comCan This Growth Stock Deliver 135% Upside in 2025?October 23, 2024 | msn.comCelldex’s Barzolvolimab Outperforms Competitor in Chronic Inducible Urticaria Market, Justifying Buy RatingOctober 16, 2024 | markets.businessinsider.comCelldex Therapeutics, Inc. (CLDX): Hedge Funds’ Hidden Gem in Small-Cap StocksOctober 16, 2024 | insidermonkey.com Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. CLDX Media Mentions By Week CLDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDX News Sentiment▼1.270.80▲Average Medical News Sentiment CLDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDX Articles This Week▼44▲CLDX Articles Average Week Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Madrigal Pharmaceuticals News Halozyme Therapeutics News Ionis Pharmaceuticals News Alkermes News Amicus Therapeutics News Ligand Pharmaceuticals News Geron News MannKind News Dynavax Technologies News BioCryst Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLDX) was last updated on 12/17/2024 by MarketBeat.com Staff From Our PartnersAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLDX Stock Alerts